Filana Therapeutics (FLNA) Non-Current Deferred Tax Liability (2010 - 2013)
Filana Therapeutics (FLNA) posted quarterly Non-Current Deferred Tax Liability of $437000.0 for Q3 2013, little changed quarter-over-quarter from $437000.0 in Q2 2013.
Filana Therapeutics (FLNA) Non-Current Deferred Tax Liability (2010 - 2013) Analysis & Trends
Filana Therapeutics' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $437000.0 for Q3 2013.
- In Q3 2013, Non-Current Deferred Tax Liability changed N/A year-over-year to $437000.0; the TTM figure through Sep 2013 stood at $437000.0 (changed N/A YoY), while the FY2012 annual figure was $437000.0, changed 0.46% from the prior year.
- Non-Current Deferred Tax Liability for Q3 2013 stood at $437000.0, roughly flat from $437000.0 in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $437000.0 in Q4 2012, with the low at $431000.0 in Q4 2010.
- The 4-year median for Non-Current Deferred Tax Liability is $437000.0 (2012), against an average of $435571.4.
- The sharpest annual moves came in 2011 and 2012: Non-Current Deferred Tax Liability advanced 0.93% in 2011, then gained 0.46% in 2012.
- Filana Therapeutics' Non-Current Deferred Tax Liability stood at $431000.0 in 2010, then advanced by 0.93% to $435000.0 in 2011, then rose by 0.46% to $437000.0 in 2012, then changed by 0.0% to $437000.0 in 2013.
- Business Quant data shows FLNA's Non-Current Deferred Tax Liability at $437000.0 in Q3 2013, $437000.0 in Q2 2013, and $437000.0 in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Filana Therapeutics | 45.29 Mn | 45.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 437,000.00 |
| Sep 30, 2013 | 437,000.00 |
| Jun 30, 2013 | 437,000.00 |
| Jun 30, 2013 | 437,000.00 |
| Mar 31, 2013 | 437,000.00 |
| Mar 31, 2013 | 437,000.00 |
| Dec 31, 2012 | 437,000.00 |
| Dec 31, 2012 | 437,000.00 |
| Mar 31, 2012 | 435,000.00 |
| Mar 31, 2012 | 435,000.00 |
| Dec 31, 2011 | 435,000.00 |
| Dec 31, 2011 | 435,000.00 |
| Dec 31, 2010 | 431,000.00 |
| Dec 31, 2010 | 431,000.00 |